Sanofi (NASDAQ:SNY) Short Interest Down 17.4% in February

Sanofi (NASDAQ:SNY) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 6,560,718 shares, a drop of 17.4% from the February 12th total of 7,942,269 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 4,224,061 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily volume of 4,224,061 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new position in Sanofi during the 4th quarter worth approximately $25,000. Financial Consulate Inc. acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $26,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $29,000. Palisade Asset Management LLC purchased a new stake in shares of Sanofi in the third quarter valued at approximately $30,000. Finally, First Horizon Corp acquired a new position in Sanofi during the third quarter worth $33,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Performance

SNY traded up $0.43 during trading on Monday, hitting $44.03. The stock had a trading volume of 707,220 shares, compared to its average volume of 4,365,155. The firm has a market capitalization of $107.39 billion, a P/E ratio of 12.23, a PEG ratio of 1.13 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a twelve month low of $43.34 and a twelve month high of $59.17. The company’s 50-day moving average price is $46.85 and its 200 day moving average price is $48.21.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SNY. HSBC reissued a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Citigroup started coverage on Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Sanofi has a consensus rating of “Hold” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.